Vaccine approaches may target peptides known to be present in HCC (e.g., AFP, GPC-3, MAGE-1, NY-ESO-1, SSX-2, and hTERT) or can be personalized for individual patients by targeting neoantigens. The gene discussed is AFP; the disease is hepatocellular carcinoma.